Cialis patent expiration

In July 2017, Eli Lilly announced that Cialis (generic name Tadalafil) would not be coming off patent protection in November of this year as was expected. They arrived at a new patent settlement with multiple generic pharmaceutical companies that extended Lilly’s protection of Cialis until September 27, 2018. The agreement was reached with multiple pharmaceutical companies and there should be some downward pressure on price due to the competition.

First approved in 2003, it has been a major source of income creating 17 billion dollars of income for Lilly.

In 2016, Cialis netted Lilly nearly 1.5 billion dollars.

In related matters, Viagra’s protection ends in 2020 but in an agreement with Teva pharmaceuticals a generic will be available nearly two years earlier in December of this year. However, unlike with Cialis, only a single pharmaceutical company will be making generic Viagra, called Sildenafil, so the pressure from competition between makers of Sildenafil will not be a factor driving down prices.

Viagra netted Pfizer a bit more than 1.5 billion dollars in 2016.